论文部分内容阅读
目的探讨放化疗不同联合模式对治疗非小细胞肺癌患者生活质量的影响。方法将151例经病理确诊的非小细胞肺癌患者按照治疗模式不同分为3组,同步放化疗组(43例)、序贯放化疗组(49例)及单纯化疗组(59例),在治疗前、后及治疗结束后1个月应用欧洲癌症研究与治疗组织(European Organization For Research Treat-ment Of Cancer,EORTC)生活质量核心问卷(QLQ-C30)对患者生存质量进行评估。结果在角色功能、情绪功能、社会功能、疲倦、恶心/呕吐、便秘方面,同步放化疗组与序贯放化疗组在治疗后积分均恶化,差异有统计学意义(P<0.05),在治疗结束后1个月两组患者积分均明显改善,差异有统计学意义(P<0.05),而单纯化疗组的社会功能在治疗结束及治疗后1个月均出现恶化,差异有统计学意义(P<0.05),恶心/呕吐、情绪功能在治疗后1个月得到改善,差异有统计学意义(P<0.05);角色功能、疲倦、便秘方面,治疗前后及治疗后1个月无明显改变(P>0.05),在躯体功能领域中同步放化疗组在治疗结束时恶化,差异有统计学意义(P<0.05),序贯放化疗组改善,差异有统计学意义(P<0.05),而在治疗结束1个月同步放化疗组改善,差异有统计学意义(P<0.05),序贯放化疗组恶化,差异有统计学意义(P<0.05);总体健康状况同步放化疗组在治疗结束1个月均得到改善,差异有统计学意义(P<0.05),而在序贯放化疗组治疗结束1个月恶化,差异有统计学意义(P<0.05),单纯化疗组则无明显变化(P>0.05);经济状况在3个组均在治疗结束及结束后1个月出现恶化,差异有统计学意义(P<0.05)。结论同期放化疗相对于单纯化疗、序贯放化疗而言,虽在治疗刚结束时躯体、角色等功能会有所下降,疲乏、恶心/呕吐等症状会加重,但在治疗后1个月这些功能、症状均得到不同的改善,总健康状况也得到明显提高。
Objective To explore the effect of different combination of radiotherapy and chemotherapy on the quality of life in patients with non-small cell lung cancer. Methods One hundred and fifteen patients with non-small cell lung cancer diagnosed by pathology were divided into three groups according to different treatment modes: concurrent chemoradiotherapy group (43 cases), sequential radiochemotherapy group (49 cases) and chemotherapy alone group (59 cases) The quality of life of the patients was assessed before and after treatment and 1 month after the end of treatment using the European Organization for Research Treat ment of Cancer (EORTC) Quality of Life Questionnaire (QLQ-C30). Results In the role of function, emotional function, social function, fatigue, nausea / vomiting and constipation, the scores of the patients in the concurrent chemoradiotherapy group and the sequential radiochemotherapy group were both worse after treatment, the difference was statistically significant (P <0.05) At 1 month after the completion of treatment, the scores of both groups were significantly improved (P <0.05), while the social function of the chemotherapy-only group was deteriorated at the end of treatment and 1 month after treatment, the difference was statistically significant ( (P <0.05). Nausea / vomiting and mood function improved at 1 month after treatment, with significant difference (P <0.05). There were no significant changes in function, fatigue, constipation, before and after treatment and 1 month after treatment (P> 0.05). In the field of somatic function, the concurrent chemoradiotherapy group was worsened at the end of treatment, the difference was statistically significant (P <0.05), sequential radiotherapy and chemotherapy group was improved, the difference was statistically significant (P <0.05) The chemoradiotherapy group was improved at 1 month after the end of treatment, the difference was statistically significant (P <0.05), sequential radiotherapy and chemotherapy group was worsened, the difference was statistically significant (P <0.05); the overall health status of concurrent radiochemotherapy group 1 month after the end of treatment were improved, the difference was statistically significant (P <0.05), while in the order There was no significant difference between the two groups (P> 0.05), but there was no significant difference between the two groups (P> 0.05). The economic status of the three groups were both at the end of the treatment and after the end of the treatment Month worsening, the difference was statistically significant (P <0.05). Conclusions Compared with chemotherapy alone and sequential chemoradiotherapy, concurrent chemoradiation may reduce the function of the body and the role at the end of treatment, and may worsen symptoms such as fatigue, nausea and vomiting. However, one month after treatment, Function, symptoms have been different improvements, the total health status has also been significantly improved.